The U.S. Food and Drug Administration (FDA) announced on Thursday that it will allow the marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests to give consumers information regarding their risk to certain diseases.
The first ever time the human genome was sequences was done in 2003. At the time it cost as much as $2.7-billion. However, DNA sequencing today wouldn't have to come off as that expensive.
You have already subscribed. Thank you.